[Congress] Drug Discovery Chemistry, May 18-19, 2021

[Congress] Drug discovery Chemistry,  May 18-19, 2021

Organised by the Cambridge Healthtech Institute, Drug Discovery Chemistry is the congress to attend! Each year, the experts' know-how is challenged by innovation to discover and optimize the small molecule drug candidate of tomorrow.

Are you looking for an integrated drug discovery services partner?

Oncodesign Service BU will attend Drug Discovery Chemistry to present DRIVE for Small Molecule, our integrated offer to guide and run your projects from hit finding to IND. You will have access to our drug discovery platforms for the design and generation of new chemical entities in several therapeutic areas – oncology, immuno-oncology, inflammatory and autoimmune diseases.
DRIVE for Small Molecule is a consortium of 5 expert companies : Oncodesign, Hitgen, Itkos, Icaria and 2bind.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Find our relatives webinars to know more about DRIVE offer.

[WEBINAR] DRIVE™: Brothers in Arms to support small molecule drug discovery from Hit to IND

[Webinar] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection

[Congress] Pharmabiotics Online, April 28-29, 2021

[Congress] Pharmabiotics Online, April 28-29, 2021

Organised by the Pharmabiotic Research Institute, Pharmabiotics is an event dedicated to medicinal microbiotic products. This event brings together online all actors involved in the international human microbiome community.

Oncodesign BU Service will be present at Pharmabiotics !

Oncodesign BU Service is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology and Inflammatory Diseases.

Discover SOLO- Microbiome: this offer enables to assist you in microbiome therapeutic project and strategy

This offering encloses multiple innovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology, pharmaco-imaging/theranostic and safety assessment all applied in one-stop shop to drug discovery programs in oncology, immuno-oncology, auto-immune/ inflammatory diseases. 

Oncodesign can be your partner:

  • •to study the relationship between imbalances in microbiota and the disease of interest,
  • •to define the role of microbiota in precision diagnosis and personalized treatment,
  • •to develop/evaluate therapeutics derived from microbiota.

Discover Oncodesign models for pathologies related to microbiota disorders and all assays/readouts that allow us to evaluate in vitro and in vivo the impact of bacteria or derived products on cancer and inflammatory diseases and the immune responses in such context.

Oncodesign models for pathologies related to microbiota disorders cancer, intestine diseases eg colitis, skin diseases eg atopic dermatitis psoriasis, metabolic diseases eg obesity diabetes, kidney diseases eg acute kidney injury, joint diseases eg rheumatoid arthritis, liver diseases eg fibrosis, lung diseases eg asthma fibrosis, graft-versus-host disease, cardiovascular diseases eg hypertension, neurological diseases eg multiple sclerosis

Set up your appointment with Emilie Soulier

[Congress] Bio Spring Europe, March 22-25, 2021

[Congress] Bio Spring Europe, March 22-25,2021

Oncodesign BU Services  and Oncodesign BU Biotech will be present at BIO SPRING Europe 2021. Find your innovative & scientific solution provider or partner!

  • •Oncodesign BU Service is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology, Infectious Diseases (Covid-19) and Inflammatory Diseases.
  • •Oncodesign BU Biotech is a clinical-stage drug discovery Business Unit that capitalizes on its next-generation kinase inhibitor technology called Nanocyclix® consisting of highly potent and selective small macrocycles to tackle novel and untractable kinases of interest.

Oncodesign Service - DRIVE-IDDS™  premium and integrated offering from Hit Finding to IND filing

This offering encloses multiple innovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology, pharmaco-imaging/theranostic and safety assessment all applied in one-stop shop to drug discovery programs in oncology, immuno-oncology, auto-immune/ inflammatory diseases. 

DRIVE-SM

DRIVE-SM is our integrated discovery engine for small molecule discovery and development - from Hit Finding to IND filing - in oncology and inflammatory diseases. Access to our multiple innovative hit-finding solutions, computational and medicinal chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology and pharmaco-imaging expertise and capabilities all in one-stop shop.

This email address is being protected from spambots. You need JavaScript enabled to view it.

DRIVE STRT

DRIVE-STRT is our new platform to enable the generation of novel systemic targeted radiotherapeutics in clinical oncology.

Oncodesign and its strategic partners are applying their expertise in the rationalization, in the design, and in the optimization of targeted radiopharmaceutical agents effective against specific cancers, with demonstration of preclinical proof of concept and safety margins, from the preclinical to the early clinical stages of your project. 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Oncodesign Biotech - Value creation through innovative technology Nanocyclix®

Using its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting both unexplored and intractable kinases in a powerful and targeted manner. The approach is "Probe based" rather than "Target based", meaning that potent and selective kinase inhibitor "Probes" are directly generated using the macrocyclic chemistry platform. These probes allow to identify accessible kinases using  a broad profiling approach and are used for early cellular Proof of Concept of the kinase(s) of interest in specific disease indications.

A large variety of kinase inhibitors are thus explored continuously, and the most promising inhibitor/targeted kinase combinations are selected for more in depth investigations. 

Oncodesign has built a project portfolio with strong potential to treat diseases with high unmet medical needs. This portfolio contains both molecules already at an advanced stage of clinical development (a PET tracer for a specific type of lung cancer) and molecules at an earlier stage of development.

Recent successes include strong advancement on LRRK2 inhibitors for Parkinson disease - a notoriously difficult kinase (in partnership with Servier), and the selection of a first in class candidate drug against the novel kinase RIPK2, a promising target in immuno-inflammation and auto-immune diseases. The latter is subject to ongoing partnering discussions and is advancing on its route towards IND in 2021

Set up your appointment with Jan Hoflack

[Congress] Microbiota & Health Day - 26 January, 2021

[Congress] Microbiota & Health Day - 26 January, 2021

Tailor-made strategies to your needs for the investigation of the efficacy of your bacteria-based treatments and/or the effect of your therapies on microbiota.

Join Dr. Sylvie Maubant and Emilie Soulier to discover how Oncodesign assess the interplay between tumor or inflammatory disease of interest (e.g. colitis), microbiota and therapies.

Our comprehensive platform dedicated to microorganisms helps you to investigate in vitro and/or in vivo the bacteria as immuno-modulating vectors or agents.

Our teams have developed models for pathologies related to microbiota disorders and therefore can customize studies for programs from preclinical to early clinical phases.

We guide you on all projects on bacteria-based therapies or any treatment acting on microbiota across different therapeutic areas i.e. oncology and inflammatory diseases.

I contact Sylvie & Emilie!

I know to know more!